THE DEAL, AT A GLANCE

RougeTx

2/4 reviewed

RougeTx

RougeTx develops oral medicines to stabilize fragile blood vessels in inherited bleeding disorders.

RougeTx raised $58M Series A, announced 2026-10-07

01What it doesRougeTx develops oral medicines to stabilize fragile blood vessels in inherited bleeding disorders.Source-grounded · automated review · Explore ↗

Checked 2026-10-07 · Review due 2026-10-14

Read supporting source ↗

RTX-001 is a small molecule…

02Who is involvedBacked by BioGeneration Ventures (BGV), Angelini Ventures, Kurma Partners, severalFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

03What happenedRougeTx raised $58M Series A, announced 2026-10-07From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

04Why it mattersThe funding supports first human testing for RTX-001, an HHT treatment candidate.Source-grounded · automated review · Explore ↗

Checked 2026-10-07 · Review due 2026-10-14

Read supporting source ↗

The money will move RTX-001…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

RougeTx · Financing Record

Explore source-linked visual explanations for RougeTx. Unsupported claims are withheld while source review continues.

Record 13581 · Recorded date: 2026-10-07

Open record 13581 →

Open record 13510 →